Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Invested Capital (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Invested Capital for 11 consecutive years, with $203.0 million as the latest value for Q4 2025.

  • Quarterly Invested Capital changed N/A to $203.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $203.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $203.0 million for FY2025, N/A changed from the prior year.
  • Invested Capital for Q4 2025 was $203.0 million at Crescent Biopharma, up from $116.6 million in the prior quarter.
  • The five-year high for Invested Capital was $203.0 million in Q4 2025, with the low at -$30.2 million in Q1 2025.
  • Average Invested Capital over 5 years is $68.9 million, with a median of $55.7 million recorded in 2022.
  • Peak annual rise in Invested Capital hit 9058.6% in 2025, while the deepest fall reached 204.32% in 2025.
  • Over 5 years, Invested Capital stood at $81.6 million in 2021, then tumbled by 47.39% to $42.9 million in 2022, then decreased by 10.52% to $38.4 million in 2023, then plummeted by 103.39% to -$1.3 million in 2024, then soared by 15692.32% to $203.0 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $203.0 million, $116.6 million, and $139.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.